LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article: Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer.

Adamaki, Maria / Zoumpourlis, Vassilios

2021 Volume 13, Issue 2

Abstract: Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the ...

Abstract	Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy, therapeutic response is usually transient, and invasive disease is associated with high mortality rates. Immunotherapy has emerged as an efficacious and non-toxic treatment alternative that perfectly fits the rationale of precision medicine, as it aims to treat patients on the basis of patient-specific, immune-targeted molecular traits, so as to achieve the maximum clinical benefit. Antibodies acting as immune checkpoint inhibitors and vaccines entailing tumor-specific antigens seem to be the most promising immunotherapeutic strategies in offering a significant survival advantage. Even though patients with localized disease and favorable prognostic characteristics seem to be the ones that markedly benefit from such interventions, there is substantial evidence to suggest that the survival benefit may also be extended to patients with more advanced disease. The identification of biomarkers that can be immunologically targeted in patients with disease progression is potentially amenable in this process and in achieving significant advances in the decision for precision treatment of PCa.
Language	English
Publishing date	2021-01-06
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13020173
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics.

Adamaki, Maria / Zoumpourlis, Vassilios

Pharmacology & therapeutics

2021 Volume 228, Page(s) 107932

Abstract: Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the leading causes of cancer-related death worldwide. It is a highly heterogeneous disease, ranging from remarkably slow progression or inertia to highly aggressive and ... ...

Abstract	Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the leading causes of cancer-related death worldwide. It is a highly heterogeneous disease, ranging from remarkably slow progression or inertia to highly aggressive and fatal disease. As therapeutic decision-making, clinical trial design and outcome highly depend on the appropriate stratification of patients to risk groups, it is imperative to differentiate between benign versus more aggressive states. The incorporation of clinically valuable prognostic and predictive biomarkers is also potentially amenable in this process, in the timely prevention of metastatic disease and in the decision for therapy selection. This review summarizes the progress that has so far been made in the identification of the genomic events that can be used for the classification, prediction and prognostication of PCa, and as major targets for clinical intervention. We include an extensive list of emerging biomarkers for which there is enough preclinical evidence to suggest that they may constitute crucial targets for achieving significant advances in the management of the disease. Finally, we highlight the main challenges that are associated with the identification of clinically significant PCa biomarkers and recommend possible ways to overcome such limitations.
MeSH term(s)	Biomarkers, Tumor/genetics ; Genomics ; Humans ; Male ; Prognosis ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2021-06-24
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	194735-7
ISSN	1879-016X ; 0163-7258
ISSN (online)	1879-016X
ISSN	0163-7258
DOI	10.1016/j.pharmthera.2021.107932
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1183: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

Maria Adamaki / Vassilios Zoumpourlis

Cancers, Vol 13, Iss 2, p

2021 Volume 173

Abstract	Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy, therapeutic response is usually transient, and invasive disease is associated with high mortality rates. Immunotherapy has emerged as an efficacious and non-toxic treatment alternative that perfectly fits the rationale of precision medicine, as it aims to treat patients on the basis of patient-specific, immune-targeted molecular traits, so as to achieve the maximum clinical benefit. Antibodies acting as immune checkpoint inhibitors and vaccines entailing tumor-specific antigens seem to be the most promising immunotherapeutic strategies in offering a significant survival advantage. Even though patients with localized disease and favorable prognostic characteristics seem to be the ones that markedly benefit from such interventions, there is substantial evidence to suggest that the survival benefit may also be extended to patients with more advanced disease. The identification of biomarkers that can be immunologically targeted in patients with disease progression is potentially amenable in this process and in achieving significant advances in the decision for precision treatment of PCa.
Keywords	prostate cancer ; immunotherapy ; precision medicine ; predictive biomarkers ; immune checkpoint inhibitors ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
Subject code	610
Language	English
Publishing date	2021-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: miRNA-Based Technologies in Cancer Therapy.

Pagoni, Maria / Cava, Claudia / Sideris, Diamantis C / Avgeris, Margaritis / Zoumpourlis, Vassilios / Michalopoulos, Ioannis / Drakoulis, Nikolaos

Journal of personalized medicine

2023 Volume 13, Issue 11

Abstract: The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA ... ...

Abstract	The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making them appealing tools for novel therapeutic approaches. This review aims to discuss miRNA biogenesis and function, as well as highlight strategies for delivering miRNA agents, presenting viral, non-viral, and exosomic delivery as therapeutic approaches for different cancer types. We also consider the therapeutic role of microRNA-mediated drug repurposing in cancer therapy.
Language	English
Publishing date	2023-11-09
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662248-8
ISSN	2075-4426
ISSN	2075-4426
DOI	10.3390/jpm13111586
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Historical retrospective of the

Simatou, Aristofania / Simatos, George / Goulielmaki, Maria / Spandidos, Demetrios A / Baliou, Stella / Zoumpourlis, Vassilios

Molecular and clinical oncology

2020 Volume 13, Issue 4, Page(s) 21

Abstract: Since its first discovery as part of the Rous sarcoma virus (RSV) genome, the c- ...

Abstract	Since its first discovery as part of the Rous sarcoma virus (RSV) genome, the c-
Language	English
Publishing date	2020-07-14
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2796865-0
ISSN	2049-9469 ; 2049-9450
ISSN (online)	2049-9469
ISSN	2049-9450
DOI	10.3892/mco.2020.2091
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.

Drillis, Georgios / Goulielmaki, Maria / Spandidos, Demetrios A / Aggelaki, Sofia / Zoumpourlis, Vassilios

Oncology letters

2021 Volume 21, Issue 5, Page(s) 393

Abstract: Contemporary developments in molecular biology have been combined with discoveries on the analysis of the role of all non-coding RNAs (ncRNAs) in human diseases, particularly in cancer, by examining their roles in cells. Currently, included among these ... ...

Abstract	Contemporary developments in molecular biology have been combined with discoveries on the analysis of the role of all non-coding RNAs (ncRNAs) in human diseases, particularly in cancer, by examining their roles in cells. Currently, included among these common types of cancer, are all the lymphomas and lymphoid malignancies, which represent a diverse group of neoplasms and malignant disorders. Initial data suggest that non-coding RNAs, particularly long ncRNAs (lncRNAs), play key roles in oncogenesis and that lncRNA-mediated biology is an important key pathway to cancer progression. Other non-coding RNAs, termed microRNAs (miRNAs or miRs), are very promising cancer molecular biomarkers. They can be detected in tissues, cell lines, biopsy material and all biological fluids, such as blood. With the number of well-characterized cancer-related lncRNAs and miRNAs increasing, the study of the roles of non-coding RNAs in cancer is bringing forth new hypotheses of the biology of cancerous cells. For the first time, to the best of our knowledge, the present review provides an up-to-date summary of the recent literature referring to all diagnosed ncRNAs that mediate the pathogenesis of all types of lymphomas and lymphoid malignancies.
Language	English
Publishing date	2021-03-18
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2021.12654
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Baliou, Stella / Kyriakopoulos, Anthony M / Spandidos, Demetrios A / Zoumpourlis, Vassilios

International journal of oncology

2020 Volume 57, Issue 3, Page(s) 631–664

Abstract: For one century, taurine is considered as an end product of sulfur metabolism. In this review, we discuss the beneficial effect of taurine, its haloamines and taurine upregulated gene 1 (TUG1) long non‑coding RNA (lncRNA) in both cancer and inflammation. ...

Abstract	For one century, taurine is considered as an end product of sulfur metabolism. In this review, we discuss the beneficial effect of taurine, its haloamines and taurine upregulated gene 1 (TUG1) long non‑coding RNA (lncRNA) in both cancer and inflammation. We outline how taurine or its haloamines (N‑Bromotaurine or N‑Chlorotaurine) can induce robust and efficient responses against inflammatory diseases, providing insight into their molecular mechanisms. We also provide information about the use of taurine as a therapeutic approach to cancer. Taurine can be combined with other chemotherapeutic drugs, not only mediating durable responses in various malignancies, but also circumventing the limitations met from chemotherapeutic drugs, thus improving the therapeutic outcome. Interestingly, the lncRNA TUG1 is regarded as a promising therapeutic approach, which can overcome acquired resistance of cancer cells to selected strategies. In this regard, we can translate basic knowledge about taurine and its TUG1 lncRNA into potential therapeutic options directed against specific oncogenic signaling targets, thereby bridging the gap between bench and bedside.
MeSH term(s)	Animals ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Disease Models, Animal ; Disease Progression ; Drug Resistance, Neoplasm/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Inflammation/drug therapy ; Inflammation/genetics ; Inflammation/immunology ; Inflammation/metabolism ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/metabolism ; Prognosis ; RNA, Long Noncoding/metabolism ; Taurine/analogs & derivatives ; Taurine/metabolism ; Taurine/pharmacology ; Taurine/therapeutic use
Chemical Substances	Anti-Inflammatory Agents ; Antineoplastic Agents ; RNA, Long Noncoding ; TUG1 long noncoding RNA, human ; Taurine (1EQV5MLY3D) ; N-chlorotaurine (51036-13-6) ; N-bromotaurine (52316-57-1)
Language	English
Publishing date	2020-07-14
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	1154403-x
ISSN	1791-2423 ; 1019-6439
ISSN (online)	1791-2423
ISSN	1019-6439
DOI	10.3892/ijo.2020.5100
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3690: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.

Baxevanis, Constantin N / Gritzapis, Angelos D / Voutsas, Ioannis F / Batsaki, Panagiota / Goulielmaki, Maria / Adamaki, Maria / Zoumpourlis, Vassilios / Fortis, Sotirios P

Cancers

2022 Volume 14, Issue 11

Abstract: Radiotherapy (RT) is a therapeutic modality that aims to eliminate malignant cells through the induction of DNA damage in the irradiated tumor site. In addition to its cytotoxic properties, RT also induces mechanisms that result in the promotion of ... ...

Abstract	Radiotherapy (RT) is a therapeutic modality that aims to eliminate malignant cells through the induction of DNA damage in the irradiated tumor site. In addition to its cytotoxic properties, RT also induces mechanisms that result in the promotion of antitumor immunity both locally within the irradiation field but also at distant tumor lesions, a phenomenon that is known as the "abscopal" effect. Because the immune system is capable of sensing the effects of RT, several treatment protocols have been assessing the synergistic role of radiotherapy combined with immunotherapy, collectively referred to as radioimmunotherapy. Herein, we discuss mechanistic insights underlying RT-based immunomodulation, which also enhance our understanding of how RT regulates antitumor T-cell-mediated immunity. Such knowledge is essential for the discovery of predictive biomarkers and for the improvement of clinical trials investigating the efficacy of radio-immunotherapeutic modalities in cancer patients.
Language	English
Publishing date	2022-05-27
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14112674
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Significance of taurine transporter (TauT) in homeostasis and its layers of regulation (Review).

Baliou, Stella / Kyriakopoulos, Anthony M / Goulielmaki, Maria / Panayiotidis, Michalis I / Spandidos, Demetrios A / Zoumpourlis, Vassilios

Molecular medicine reports

2020 Volume 22, Issue 3, Page(s) 2163–2173

Abstract: Taurine (2‑aminoethanesulfonic acid) contributes to homeostasis, mainly through its antioxidant and osmoregulatory properties. Taurine's influx and efflux are mainly mediated through the ubiquitous expression of the sodium/chloride‑dependent taurine ... ...

Abstract	Taurine (2‑aminoethanesulfonic acid) contributes to homeostasis, mainly through its antioxidant and osmoregulatory properties. Taurine's influx and efflux are mainly mediated through the ubiquitous expression of the sodium/chloride‑dependent taurine transporter, located on the plasma membrane. The significance of the taurine transporter has been shown in various organ malfunctions in taurine‑transporter‑null mice. The taurine transporter differentially responds to various cellular stimuli including ionic environment, electrochemical charge, and pH changes. The renal system has been used as a model to evaluate the factors that significantly determine the regulation of taurine transporter regulation.
MeSH term(s)	Animals ; Feces/chemistry ; Homeostasis ; Humans ; Hydrogen-Ion Concentration ; Kidney/chemistry ; Membrane Glycoproteins/metabolism ; Membrane Transport Proteins/metabolism ; Mice ; Taurine/analogs & derivatives ; Taurine/metabolism ; Taurine/urine
Chemical Substances	Membrane Glycoproteins ; Membrane Transport Proteins ; taurine transporter (148686-53-7) ; Taurine (1EQV5MLY3D) ; 2-aminoethanethiosulfonic acid (2937-54-4)
Language	English
Publishing date	2020-07-09
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2469505-1
ISSN	1791-3004 ; 1791-2997
ISSN (online)	1791-3004
ISSN	1791-2997
DOI	10.3892/mmr.2020.11321
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: [Comment] The COVID‑19 pandemic as a scientific and social challenge in the 21st century.

Zoumpourlis, Vassilios / Goulielmaki, Maria / Rizos, Emmanouil / Baliou, Stella / Spandidos, Demetrios A

Molecular medicine reports

2020 Volume 22, Issue 4, Page(s) 3035–3048

Abstract: The coronavirus disease‑2019 (COVID‑19) pandemic, caused by the new coronavirus SARS‑CoV‑2, has spread around the globe with unprecedented consequences for the health of millions of people. While the pandemic is still in progress, with new incidents ... ...

Abstract	The coronavirus disease‑2019 (COVID‑19) pandemic, caused by the new coronavirus SARS‑CoV‑2, has spread around the globe with unprecedented consequences for the health of millions of people. While the pandemic is still in progress, with new incidents being reported every day, the resilience of the global society is constantly being challenged. Under these circumstances, the future seems uncertain. SARS‑CoV‑2 coronavirus has spread panic among civilians and insecurity at all socio‑political and economic levels, dramatically disrupting everyday life, global economy, international travel and trade. The disease has also been linked to the onset of depression in many individuals due to the extreme restriction measures that have been taken for the prevention of the rapid spreading of COVID‑19. First, the socio‑economic, political and psychological implications of the COVID‑19 pandemic were explored. Substantial evidence is provided for the consequences of the pandemic on all aspects of everyday life, while at the same time we unravel the role and the pursuits of national regimes during this unforeseen situation. The second goal of this review is related to the scientific aspect of the pandemic. Hence, we explain why SARS‑CoV‑2 is not a so‑called 'invisible enemy', and also attempt to give insight regarding the origin of the virus, in an effort to reject the conspiracy theories that have arisen during the pandemic. Finally, rational strategies were investigated for successful vaccine development. We are optimistic that this review will complement the knowledge of specialized scientists and inform non‑specialized readers on basic scientific questions, and also on the social and economic implications of the COVID‑19 pandemic.
MeSH term(s)	COVID-19 ; Coronavirus Infections/psychology ; Cost of Illness ; Humans ; Pandemics ; Pneumonia, Viral/psychology ; Politics ; Science ; Social Class ; Socioeconomic Factors ; Viral Vaccines
Chemical Substances	Viral Vaccines
Keywords	covid19
Language	English
Publishing date	2020-07-30
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2469505-1
ISSN	1791-3004 ; 1791-2997
ISSN (online)	1791-3004
ISSN	1791-2997
DOI	10.3892/mmr.2020.11393
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito